Faster Trial Starts Need A Site Readiness Receipt

Contributed Commentary by Gleb Tsipursky 

November 17, 2026 | Clinical research teams have spent years trying to shorten the wait between a promising therapeutic idea and the first participant visit. When those efforts succeed, they will create a different bottleneck: sites asked to move faster through screening, documentation, and activation with no additional room for ambiguity. I would like sponsors to start measuring one thing before celebrating an accelerated timeline: whether the site can explain and correct the critical decisions made along the way. 

The immediate reason is the FDA’s new Expedited Investigational New Drug pilot, whose application window runs through October 30, 2026. The pilot invites eligible sponsors to work with qualified research institutions on rolling review of parts of an IND application and encourages coordination with site activation and institutional review board work when appropriate. This is a defined pilot, rather than a new general requirement for every sponsor. It nevertheless makes the question of readiness timely for the industry. 

At the same time, researchers are using AI to find potential participants and organize trial work. In April, Clinical Research News reported on an AI-assisted Cleveland Clinic screening project that coupled electronic-record screening with clinician review. The story demonstrates why the relationship between automated preparation and qualified human review deserves operational attention. A screening tool can surface an opportunity that a manual process missed, while the responsibility to interpret eligibility and communicate with participants remains with the research team. 

Consider a hypothetical multi-site study preparing to start enrollment. A tool produces a list of potential candidates and a neat readiness summary for the sponsor. One site has a current laboratory capacity limitation. Another site uses a different version of the screening criteria than the one embedded in the tool. A third can technically recruit, but its consent process requires an additional accommodation that the summary does not show. All three sites appear green on a dashboard. The first week of enrollment quickly tells a different story. 

This is the danger of treating an automated status report as if it were an operational decision. The report may be internally consistent and still omit the exception that decides whether the next step is appropriate. Sponsors need a compact record of those exceptions, with a named person who owns each resolution. 

I call that a site readiness receipt. It should accompany any AI-assisted screening or activation summary that will influence a consequential study decision. First, record the version of the protocol and eligibility criteria used by the system, along with when relevant site data were last refreshed. Second, identify which items were independently checked by the site: eligibility flags, contact preferences, laboratory or pharmacy constraints, and any local process limitation. Third, capture the unresolved exceptions and the individual who has authority to approve or pause each action. Finally, document what changed after human review. 

None of this requires the sponsor to turn every staff member into a technical specialist. It requires deciding what a research coordinator, investigator, data manager, and sponsor operations lead must each understand well enough to challenge. A coordinator who sees a conflicting record needs to know the path to clarification. An investigator must remain responsible for clinical eligibility judgments. A data manager needs a traceable correction history. The sponsor should be able to see whether a delay reflects slow work or an issue the automated workflow failed to reveal. 

Training should follow those roles. Rather than awarding staff a generic AI proficiency certificate, hand them a realistic case in which one piece of site information is missing. Ask them to find the gap and show how they would resolve it without exposing participant information in an unapproved system. Run a second case in which the machine’s ranking is plausible but the source record is out of date. Measure whether staff recognize that ambiguity and route it to the right person. A short exercise repeated after protocol amendments is more revealing than a course attendance count. 

Organizations can make reporting errors more productive by separating the identification of an exception from blame. If the first coordinator to say ‘the system missed something’ receives criticism for slowing activation, a sponsor will hear fewer warnings. Teams need explicit permission to challenge a summary and a normal place in the operating meeting to discuss corrections. This also helps distinguish a genuine technical failure from a workflow that nobody has clearly assigned. 

The receipt should connect to measures that sponsors already care about. Record elapsed time from a candidate signal to an investigator decision, but also count candidates rejected after avoidable rework. Track the rate of screening exceptions resolved within the agreed interval. Compare planned activation dates with actual readiness, and identify which delays came from missing data or ambiguous ownership. When a protocol amendment lands, test whether the updated criteria reach every system and staff member before new decisions are made. 

Those measures create more credible speed claims. A tool that reduces document preparation time but increases unnecessary eligibility escalations has shifted work, not necessarily removed it. A site that completes its check in a slightly longer interval but catches a serious inconsistency has prevented a downstream delay or quality problem. Sponsors should look for both kinds of evidence rather than awarding all credit to the shortest clock. 

The FDA’s broader clinical-development modernization agenda<https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development> emphasizes reducing avoidable delays while maintaining scientific oversight and participant protection. Site readiness receipts support the same practical objective without implying that the FDA mandates a particular AI workflow. A sponsor can adopt them as an internal operating standard today. 

Clinical research has learned to measure the time from one milestone to the next. The industry’s next advantage will come from making the reasoning between those milestones visible. If faster IND preparation and smarter screening bring more opportunities to the site, an auditable decision record will help teams move quickly without losing the human knowledge that gives those decisions meaning. 

Gleb Tsipursky, PhD, a behavioral scientist, CEO of Disaster Avoidance Experts, and author of The Psychology of AI Adoption at Work: From Resistance to Results (Georgetown University Press, 2026) https://disasteravoidanceexperts.com/aibook. He can be reached at gleb@disasteravoidanceexperts.com.  

Load more comments
comment-avatar